SOURCE: Paragon Financial Limited

Paragon Financial Limited

November 17, 2011 08:16 ET

Cheap Valuations and Acquisition Speculation Driving Biotech Shares Higher

The Bedford Report Provides Equity Research on Cell Therapeutics & Human Genome Sciences

NEW YORK, NY--(Marketwire - Nov 17, 2011) - Despite disappointing third quarter results for some of biotechnology's up-and-coming stars, there is plenty of optimism in the industry. According to Lipper Inc. healthcare and biotechnology stock funds are up 17 percent this year and 35 percent over the past 12 months. Healthcare stocks underperformed during last year's market rally, and Andy Oh, research analyst and portfolio manager of the Fidelity Select Pharmaceuticals Fund argues that investors are embracing the "cheap valuations in health care stocks." The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Cell Therapeutics, Inc. (NASDAQ: CTIC) and Human Genome Sciences, Inc. (NASDAQ: HGSI). Access to the full company reports can be found at:

www.paragonreport.com/CTIC

www.paragonreport.com/HGSI

The increase in M&A activity in the healthcare sector is yet another reason investors are once again taking a close look at biotech stocks. Michael Gregory, portfolio manager of the Highland Long/Short Health care Fund argues that "acquisitions are needed to fuel growth" as government intervention suppresses growth in larger firms. Moreover, Big Pharma companies are about to face the largest patent expiration cliff in the industry's history and will need to fill the gap of lost income.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

Cancer is projected to become the leading cause of death worldwide this year by the World Health Organisation, and has already emerged as the most expensive disease - costing the global economy nearly a trillion dollars a year. With cancer drugs alone costing the United States more than $30 million a year, it is clearly a lucrative sector for drug makers.

Earlier this year Human Genome Sciences Inc. said it has agreed with FivePrime Therapeutics Inc. to develop and bring to market a drug for treating several types of cancer. Under the terms of the agreement between the two companies, Human Genome Sciences received exclusive rights to develop and commercialize the drug in the US, Canada and European Union.

Cell Therapeutics is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. The company says that its drug candidate Pixantrone "is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents."

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer